CD4/CD8 Double-Positive T Cell Production via p38 Inhibitor and SDF-1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing T lymphocytes from hematopoietic progenitor cells and pluripotent stem cells face inefficiencies and challenges in differentiation and gene transfer, leading to insufficient production of CD4/CD8 double-positive T cells.
Innovation Solution
Culturing hematopoietic progenitor cells in a medium supplemented with a p38 inhibitor and/or SDF-1, such as SB203580 and SDF-1α, to efficiently induce CD4/CD8 double-positive T cells, which can then be differentiated into CD8-positive T cells using an adrenocortical hormone agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to induce CD4/CD8 double-positive T cells from hematopoietic progenitor cells, then the differentiation process can proceed, but the production efficiency is insufficient
Solution Approach 1:
The invention changes the chemical parameters of the culture medium by adding a p38 inhibitor (such as SB203580) and SDF-1 (stromal cell-derived factor 1) to optimize the differentiation conditions. This parameter modification significantly improves both the production efficiency and reliability of CD4/CD8 double-positive T cells by enhancing the differentiation process from hematopoietic progenitor cells.
Solution Approach 2:
The invention introduces intermediary substances (p38 inhibitor and SDF-1) into the culture system to mediate and enhance the differentiation process. These intermediaries act as signaling molecules that facilitate the transformation of hematopoietic progenitor cells into CD4/CD8 double-positive T cells, thereby improving production efficiency without compromising differentiation quality.
2Adaptability or versatility
If gene transfer is performed into lymphoid cells to enable specific immune reaction, then antigen-specific immunity can be achieved, but gene transfer efficiency is low and differentiation regulation is difficult
Solution Approach 1:
The invention performs preliminary differentiation of hematopoietic progenitor cells into CD4/CD8 double-positive T cells using optimized culture conditions (with p38 inhibitor and SDF-1) before conducting gene transfer. This preliminary action creates a more suitable cellular target for gene transfer, improving both the ease of manufacture and the effectiveness of subsequent antigen-specific immune response generation.
3Adaptability or versatility
If T lymphocytes are induced from pluripotent stem cells through multiple steps, then replacement therapy can be pursued, but the overall production efficiency is insufficient
Solution Approach 1:
The invention modifies the culture medium parameters by incorporating a p38 inhibitor and SDF-1 during the critical differentiation step to generate CD4/CD8 double-positive T cells from pluripotent stem cells. This parameter change significantly boosts the production efficiency of T lymphocytes while maintaining their functionality for replacement therapy applications.
Solution Approach 2:
The invention ensures continuous optimization of the differentiation process by maintaining appropriate concentrations of p38 inhibitor and SDF-1 throughout the culture period. This continuous action ensures steady and efficient production of CD4/CD8 double-positive T cells from pluripotent stem cells, enabling scalable production for therapeutic purposes.
Data Source
AI summary
A method for producing CD4/CD8 double-positive T cells, comprising the steps of: (1) culturing pluripotent stem cells in a medium to induce hematopoietic progenitor cells; and (2) culturing the hematopoietic progenitor cells obtained in the step (1) in a medium containing a p38 inhibitor and/or SDF-1 to induce CD4/CD8 double-positive T cells.